VOL. XCIV, NO. 247

★ MOAT STOCKS & COMPETITIVE ADVANTAGES ★

PRICE: 5 CENTS

Thursday, December 25, 2025

Zimmer Biomet Holdings, Inc.

ZBH · New York Stock Exchange

active
Market cap (USD)
SectorHealthcare
CountryUS
Data as of
Moat score
72/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Zimmer Biomet is a global orthopedic medical-device company focused on knee and hip reconstruction, plus adjacent sports medicine/extremities/trauma and a growing robotics/digital offering. Its moat is primarily surgeon- and workflow-based: dense local sales/clinical support, consignment-heavy logistics, and procedural familiarity with instrument sets and systems. Regulatory clearance/quality systems are table-stakes barriers that still slow entrants. In large joints, third-party industry data shows Zimmer Biomet as a leading share holder in knees and hips worldwide (2023).

Primary segment

Knees

Market structure

Oligopoly

Market share

30.1% (reported)

HHI: 2,265

Coverage

4 segments · 5 tags

Updated 2025-12-23

Segments

Knees

Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation

Revenue

41.3%

Structure

Oligopoly

Pricing

moderate

Share

30.1% (reported)

Peers

SYKJNJSNN

Hips

Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation

Revenue

26%

Structure

Oligopoly

Pricing

moderate

Share

23.5% (reported)

Peers

SYKJNJSNN

S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)

Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices

Revenue

24.3%

Structure

Competitive

Pricing

weak

Share

Peers

SYKJNJSNN

Technology & Data, Bone Cement and Surgical

Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments

Revenue

8.3%

Structure

Oligopoly

Pricing

moderate

Share

Peers

SYKJNJMDTISRG

Moat Claims

Knees

Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation

Oligopoly

Design In Qualification

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Knee systems are embedded in surgeon preference and OR workflow; adoption requires system-specific training and familiarity (instrument sets, technique, rep support).

Erosion risks

  • Hospital standardization reduces surgeon choice
  • New implant designs narrow differentiation
  • Shift of volume to price-sensitive ambulatory surgery centers

Leading indicators

  • Knee share trend vs SYK/JNJ/SNN
  • Pricing realization (net price/mix)
  • Adoption rates of new knee platforms and robotics-assisted procedures

Counterarguments

  • Surgeons can switch with retraining; competitors also run extensive education programs
  • Hospitals can force standardization via tenders and bundled purchasing

Service Field Network

Supply

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Dense field support and consignment-heavy logistics improve case coverage and service reliability at the facility level.

Erosion risks

  • Distributor/channel disruption
  • ERP/logistics execution issues
  • Hospital consolidation reduces the value of local density

Leading indicators

  • Backorder/fill-rate metrics
  • Rep productivity and churn
  • Customer complaint / service levels

Counterarguments

  • Large competitors have comparable field organizations and consignment models
  • Health systems may centralize inventory and reduce vendor footprint

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Medical device regulatory clearance and quality systems create meaningful barriers to entry and slow product cycles for new competitors.

Erosion risks

  • Quality failures/recalls can damage credibility and disrupt supply
  • Regulatory tightening increases cost and delays innovation

Leading indicators

  • Regulatory warning letters / inspection outcomes
  • Recall frequency and severity

Counterarguments

  • Regulatory requirements apply equally to incumbents; not a unique advantage by itself

Benchmark Pricing Power

Financial

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Some ability to realize price (especially on differentiated systems), tempered by hospital procurement and competitive bidding.

Erosion risks

  • Aggressive tendering and reference pricing
  • Competitor discounting to gain share

Leading indicators

  • Gross margin trend and price/mix commentary
  • GPO contract win/loss outcomes

Counterarguments

  • Large joints are mature categories where purchasers can extract price concessions over time

Hips

Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation

Oligopoly

Design In Qualification

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Hip systems are procedure-embedded; surgeon familiarity and instrument ecosystems create meaningful switching/qualification costs.

Erosion risks

  • Commoditization of stems/cups
  • Purchaser-driven standardization and tendering

Leading indicators

  • Hip share trend vs SYK/JNJ/SNN
  • Revision mix and outcomes data publications

Counterarguments

  • Competitors offer comparable implant platforms and education programs

Service Field Network

Supply

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Local field coverage and consigned inventory support case readiness and responsiveness at the account level.

Erosion risks

  • Distributor instability in certain regions
  • Execution issues that reduce service levels

Leading indicators

  • Order fill rates and backorders
  • Regional growth vs market

Counterarguments

  • Incumbent peers also operate large field organizations

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Regulatory approval and ongoing quality-system compliance lengthen development cycles and add entry barriers for new products.

Erosion risks

  • Regulatory tightening (e.g., post-market surveillance burdens)
  • Quality remediation/inspection findings

Leading indicators

  • Approval/clearance timelines for new hip systems
  • Regulatory enforcement actions

Counterarguments

  • Barrier affects all incumbents; differentiation comes more from commercial execution and clinical preference

Benchmark Pricing Power

Financial

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Limited but present price realization; negotiated contracts and competitive bids cap upside.

Erosion risks

  • Hospital consolidation and stronger purchasing leverage

Leading indicators

  • Gross margin and price/mix disclosure
  • Competitive win/loss commentary in earnings

Counterarguments

  • Large-joint categories often see long-term ASP pressure despite innovation cycles

S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)

Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices

Competitive

Scope Economies

Supply

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Broad portfolio across multiple subcategories can leverage shared sales coverage, education, and account access.

Erosion risks

  • Best-of-breed specialists out-innovate in subcategories
  • Private competitors with deep focus win surgeon mindshare

Leading indicators

  • Growth vs category benchmarks (sports med, extremities, trauma)
  • Mix shift toward faster-growing subcategories

Counterarguments

  • Scope can dilute focus; category leaders may still win with superior products

Service Field Network

Supply

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Field support and medical education help drive adoption and utilization across procedure types.

Erosion risks

  • Distributor turnover in smaller markets
  • Margin pressure reduces ability to fund field headcount

Leading indicators

  • Salesforce productivity
  • Service-level metrics (fill rates, instrument availability)

Counterarguments

  • Peers also have sizable field teams; differentiation depends on execution

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Ongoing regulatory compliance and post-market obligations slow entrants and increase costs for smaller competitors.

Erosion risks

  • Quality issues trigger recalls and reputational damage

Leading indicators

  • Inspection outcomes and remediation spending

Counterarguments

  • Regulation is necessary but not sufficient for differentiation in highly competitive subcategories

Technology & Data, Bone Cement and Surgical

Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments

Oligopoly

Ecosystem Complements

Network

Strength: 4/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Robotics/digital tools are more valuable when integrated with the broader implant/instrument ecosystem; hospitals may prefer fewer integrated platforms.

Erosion risks

  • Competing robotics platforms gain surgeon preference
  • Hospitals standardize on a rival platform across service lines

Leading indicators

  • Installed base of robotic systems
  • Utilization per installed robot
  • Attach rate of implants/instruments with robotic procedures

Counterarguments

  • Hospitals can run multiple platforms; integration benefits may not prevent switching
  • Competitors are also building end-to-end ecosystems

Data Workflow Lockin

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Digital platforms and remote monitoring can embed the company into care pathways and value-based workflows, increasing switching friction over time.

Erosion risks

  • Interoperability standards reduce lock-in
  • Hospitals prefer vendor-neutral platforms

Leading indicators

  • Active users on digital platforms
  • Retention of facilities using digital + implant bundles

Counterarguments

  • Many providers resist closed ecosystems; data portability can limit switching costs

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Robotics/software-as-medical-device features add incremental regulatory oversight and compliance burden.

Erosion risks

  • Regulatory changes for AI/ML and software devices
  • Cybersecurity incidents increase scrutiny and costs

Leading indicators

  • Clearance/approval cadence for new modules
  • Security and safety incident rate

Counterarguments

  • Regulatory barriers apply broadly; market leadership depends on outcomes, usability, and economics

Evidence

sec_filing
Zimmer Biomet Annual Report (Form 10-K), FY ended 2024-12-31

We invest a significant amount of time and expense in training sales associates...

Supports qualification/training intensity and workflow reliance around product-specific usage.

sec_filing
Zimmer Biomet Annual Report (Form 10-K), FY ended 2024-12-31

Consignment sales represented approximately 85 percent of our net sales in 2024.

Consignment plus local inventory/rep coverage increases service levels and raises the operational cost of switching vendors.

sec_filing
Zimmer Biomet Annual Report (Form 10-K), FY ended 2024-12-31

All of our devices marketed in the U.S. have been cleared or approved by the FDA...

Documents the baseline regulatory hurdle and ongoing compliance burden.

sec_filing
Zimmer Biomet Annual Report (Form 10-K), FY ended 2024-12-31

Net sales growth was driven by... positive price realization...

Supports the claim that the company achieved positive pricing contribution in 2024.

industry_report
2024 Hip and Knee Implant Review (AAHKS / Curvo Labs; ORTHOWORLD data)

Zimmer Biomet led... the knee... market with 30.1%... share...

Directly states 2023 worldwide knee implant share for Zimmer Biomet.

Showing 5 of 17 sources.

Risks & Indicators

Erosion risks

  • Hospital standardization reduces surgeon choice
  • New implant designs narrow differentiation
  • Shift of volume to price-sensitive ambulatory surgery centers
  • Distributor/channel disruption
  • ERP/logistics execution issues
  • Hospital consolidation reduces the value of local density

Leading indicators

  • Knee share trend vs SYK/JNJ/SNN
  • Pricing realization (net price/mix)
  • Adoption rates of new knee platforms and robotics-assisted procedures
  • Backorder/fill-rate metrics
  • Rep productivity and churn
  • Customer complaint / service levels
Created 2025-12-23
Updated 2025-12-23

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.